Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
binimetinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Binimetinib + paclitaxel is a **combination therapy** of an oral MEK inhibitor, binimetinib, and an intravenous microtubule stabilizer, paclitaxel, investigated primarily for platinum-resistant epithelial ovarian cancer. Binimetinib is a highly selective, non-ATP competitive inhibitor of MEK1 and MEK2 within the MAPK pathway, while paclitaxel is a mitotic inhibitor that promotes tubulin polymerization and inhibits cell division. The combination aims for synergistic antitumor activity—MEK inhibition may sensitize tumors to taxane-induced apoptosis. The regimen’s efficacy and safety has been evaluated in phase Ib clinical trials, with the recommended phase 2 dosing of binimetinib at 30 mg orally twice daily (continuous) or 45 mg orally twice daily (intermittent), together with paclitaxel 80 mg/m^2^ intravenously weekly. The principal indication under investigation is platinum-resistant ovarian cancer. The developer of binimetinib is Array BioPharma; paclitaxel is widely produced by various manufacturers.
- Other names
- binimetinib + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)
Beyond the preview
Go deeper on binimetinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on binimetinib + paclitaxel.